ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last1,361 to 1,380 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Adults on CSII Treatment vs Paediatric Patients on CSII Treatment: Number of Patients With HbA1c on Target Using Advanced Pump's Functions, CGM and CHO Counting1,713 of 5,598

515 of 1,025

-19.6 points

-22.9 to -16.4

6,623NCT02620917

Continuos Subcutaneous Insulin Infusion in Italy

Adults on CSII Treatment vs Paediatric Patients on CSII Treatment: Number of Patients With Glycated Hemoglobin on Target1,288 of 5,598

445 of 1,025

-20.4 points

-23.6 to -17.2

6,623NCT02620917

Continuos Subcutaneous Insulin Infusion in Italy

Palivizumab vs Motavizumab: Number of Participants Reporting Any Related AEs258 of 3,298

298 of 3,315

-1.2 points

-2.5 to 0.2

6,613NCT00129766

Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

Palivizumab vs Motavizumab: Number of Participants Reporting Any Related SAEs8 of 3,298

9 of 3,315

-0.0 points

-0.3 to 0.2

6,613NCT00129766

Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

Palivizumab vs Motavizumab: Number of Participants Reporting Any Adverse Events (AEs)2,837 of 3,298

2,839 of 3,315

0.4 points

-1.3 to 2.1

6,613NCT00129766

Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

Palivizumab vs Motavizumab: Number of Participants Who Discontinued Study Drug Due to AEs10 of 3,298

13 of 3,315

-0.1 points

-0.4 to 0.2

6,613NCT00129766

Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

Palivizumab vs Motavizumab: Number of Participants Reporting Any Serious Adverse Events (SAEs)506 of 3,298

485 of 3,315

0.7 points

-1.0 to 2.4

6,613NCT00129766

Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

Palivizumab vs Motavizumab: Number of Participants Who Died4 of 3,298

8 of 3,315

-0.1 points

-0.4 to 0.1

6,613NCT00129766

Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

Palivizumab vs Motavizumab: serious adverse events506 of 3,298

485 of 3,315

0.7 points

-1.0 to 2.4

6,613NCT00129766

Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

Empagliflozin 10 mg vs Placebo: deaths from any cause314 of 3,304

353 of 3,305

-1.2 points

-2.6 to 0.3

6,609NCT03594110

EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

Empagliflozin 10 mg vs Placebo: serious adverse events1,089 of 3,304

1,167 of 3,305

-2.4 points

-4.6 to -0.1

6,609NCT03594110

EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od: Primary Efficacy Outcome: Number of Participants With Composite of Myocardial Infarction (MI), Ischemic Stroke, Cardiovascular Death, Acute Limb Ischemia (ALI) and Major Amputation Due to a Vascular Etiology508 of 3,286

584 of 3,278

-2.4 points

-4.2 to -0.6

6,564NCT02504216

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od: Number of Participants With Composite of MI, Ischemic Stroke, All-cause Mortality (ACM), ALI, and Major Amputation of a Vascular Etiology614 of 3,286

679 of 3,278

-2.0 points

-4.0 to -0.1

6,564NCT02504216

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od: Number of Participants With Composite of MI, Ischemic Stroke, Coronary Heart Disease (CHD) Death, ALI, and Major Amputation of a Vascular Etiology433 of 3,286

528 of 3,278

-2.9 points

-4.6 to -1.2

6,564NCT02504216

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od: Number of Participants With Composite of MI, All-cause Stroke, Cardiovascular (CV) Death, Acute Limb Ischemia (ALI), and Major Amputation of a Vascular Etiology514 of 3,286

588 of 3,278

-2.3 points

-4.1 to -0.5

6,564NCT02504216

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od: Number of Participants With Hospitalization for a Coronary or Peripheral Cause (Either Lower Limb) of a Thrombotic Nature262 of 3,286

356 of 3,278

-2.9 points

-4.3 to -1.5

6,564NCT02504216

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od: Number of Mortality (All-cause)321 of 3,286

297 of 3,278

0.7 points

-0.7 to 2.1

6,564NCT02504216

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od: Number of Participants With an Unplanned Index Limb Revascularization for Recurrent Limb Ischemia (Subsequent Index Leg Revascularization That Was Not Planned or Considered as Part of the Initial Treatment Plan at the Time of Randomization)584 of 3,286

655 of 3,278

-2.2 points

-4.1 to -0.3

6,564NCT02504216

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od: Number of Participants With Venous Thromboembolic (VTE) Events25 of 3,286

41 of 3,278

-0.5 points

-1.0 to -0.0

6,564NCT02504216

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Active Vitamin E vs Vitamin E Placebo: Effect of Vitamin E on CRA Occurrence, Analyzed by Active Vitamin E vs. Vitamin E Placebo1,159 of 3,269

1,127 of 3,277

1.1 points

-1.2 to 3.4

6,546NCT00706121

S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=69

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02620917-48356c6e",
        "title": "Adults on CSII Treatment vs Paediatric Patients on CSII Treatment: Number of Patients With HbA1c on Target Using Advanced Pump's Functions, CGM and CHO Counting",
        "summary": "1713 of 5598 against 515 of 1025; risk difference -19.6 points, 95% interval -22.9 to -16.4; NCT02620917, Continuos Subcutaneous Insulin Infusion in Italy",
        "record": "/library/comparisons/NCT02620917-48356c6e",
        "nct_id": "NCT02620917",
        "kind": "outcome",
        "participants": 6623,
        "risk_difference": {
          "value": -0.19643688076752153,
          "lower": -0.2292289188169661,
          "upper": -0.16353015332702361
        },
        "group_1": "1,713 of 5,598",
        "group_2": "515 of 1,025",
        "difference": "-19.6 points",
        "interval": "-22.9 to -16.4",
        "trial_title": "Continuos Subcutaneous Insulin Infusion in Italy"
      },
      {
        "id": "NCT02620917-aa213537",
        "title": "Adults on CSII Treatment vs Paediatric Patients on CSII Treatment: Number of Patients With Glycated Hemoglobin on Target",
        "summary": "1288 of 5598 against 445 of 1025; risk difference -20.4 points, 95% interval -23.6 to -17.2; NCT02620917, Continuos Subcutaneous Insulin Infusion in Italy",
        "record": "/library/comparisons/NCT02620917-aa213537",
        "nct_id": "NCT02620917",
        "kind": "outcome",
        "participants": 6623,
        "risk_difference": {
          "value": -0.20406416925905593,
          "lower": -0.23646370797639502,
          "upper": -0.17200012098806894
        },
        "group_1": "1,288 of 5,598",
        "group_2": "445 of 1,025",
        "difference": "-20.4 points",
        "interval": "-23.6 to -17.2",
        "trial_title": "Continuos Subcutaneous Insulin Infusion in Italy"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=70",
  "request_id": "fcBFqtGhV2BIetLq"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?